Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Alan Lau"'
Autor:
Zena Wilson, Rajesh Odedra, Yann Wallez, Paul W.G. Wijnhoven, Adina M. Hughes, Joe Gerrard, Gemma N. Jones, Hannah Bargh-Dawson, Elaine Brown, Lucy A. Young, Mark J. O'Connor, Alan Lau
Publikováno v:
Cancer Research. 82:1140-1152
AZD6738 (ceralasertib) is a potent and selective orally bioavailable inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. ATR is activated in response to stalled DNA replication forks to promote G2–M cell-cycle checkpoints and fork res
Autor:
Alan Lau, Susan Galbraith, Sonja J. Gill, Mark J. O'Connor, Joshua Armenia, Jacqueline H. L. Fok, Conchita Vens, Rebecca L. Lloyd, Jonathan Cairns, Jenni Nikkilä, Christopher J. Bakkenist, Paul W. G. Wijnhoven
Publikováno v:
Mol Cancer Ther
Radiotherapy is an effective anticancer treatment, but combinations with targeted agents that maximize efficacy while sparing normal tissue are needed. Here, we assess the radiopotentiation profiles of DNA damage response inhibitors (DDRi) olaparib (
Autor:
Anna Przybyla, Chetan Rane, Gopi Patel, Deepa Bhavsar, Shenghua Wen, David Clark, Yeoun Jin Kim, Alan Lau, Yann Wallez, Jay Mettetal, Wenyan Zhong, Matthew Sung
Publikováno v:
Cancer Research. 83:LB227-LB227
Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate (ADC) consisting of a humanized anti-TROP2 IgG1 monoclonal antibody covalently linked to a highly potent topoisomerase I (TOP1) inhibitor payload via a stable, tumor-selective, tetrapept
Autor:
Gemma N. Jones, Sonia Iyer, Marta Milo, Pei-Jen Lou, Melonie A. Nance, Carlos A. Gomez-Roca, Nathan Standifer, Paola Marco-Casanova, Shaan Gill, Michael Surace, Richard Bystry, Maria Alexandrova, Sophie Willis, Jaime Rodriguez-Canales, Andreas Dannhorn, Bienvenu Loembé, Alan Lau, Natalia Lukashchuk, Elizabeth A. Harrington, Elhan Sanai, Emma Dean, Umamaheswar Duvvuri
Publikováno v:
Cancer Research. 83:CT198-CT198
Head and neck squamous cell carcinoma (HNSCC) is frequently locally advanced, but has a high risk of recurrence after initial treatment. Immune checkpoint blockade with PD-1/PD-L1 inhibitors has revolutionized treatment in the recurrent setting, but
Autor:
Keun-Wook Lee, Natasha Lukashchuk, Andrew Goldwin, Bienvenu Loembe, Graeme Parr, Irene Kang, Tobias Arkenau, R Roylance, Mario Campone, Claire Smith, Wassim Abida, Andrew J. Pierce, Duncan I. Jodrell, Alan Lau, Elhan Sanay, Sophie Postel-Vinay, Juanita Lopez, Sunyoung Rha, Emma Dean, Matthew G Krebs, Seock-Ah Im
Publikováno v:
Cancer Research. 81:PS11-18
Background: Alterations in BRCA1/2 are associated with ~9% of all BCs. Ola (a poly ADP-ribose polymerase inhibitor [PARPi]) is approved for treating pts with HER2-negative metastatic BC with germline BRCA mutation (gBRCAm), demonstrating an improveme
Autor:
Matthew J. Sale, Luis Tobalina, Alan Lau, Elizabeth A. Coker, Elisabetta Leo, Andrew J. Pierce, Anderson T. Wang, Violeta Serra, Mark J. O'Connor, Tarrion Baird, Gemma N Jones, Tudor Petreus, Patricia Jaaks, Joshua Armenia, Claudia Winkler, Mathew J. Garnett
Publikováno v:
British Journal of Cancer. 124:951-962
Background Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a comprehensive analysis of the clinic
Autor:
Violeta Serra, Anderson T. Wang, Marta Castroviejo-Bermejo, Urszula M. Polanska, Marta Palafox, Andrea Herencia-Ropero, Gemma N. Jones, Zhongwu Lai, Joshua Armenia, Filippos Michopoulos, Alba Llop-Guevara, Rachel Brough, Aditi Gulati, Stephen J. Pettitt, Krishna C. Bulusu, Jenni Nikkilä, Zena Wilson, Adina Hughes, Paul W.G. Wijnhoven, Ambar Ahmed, Alejandra Bruna, Albert Gris-Oliver, Marta Guzman, Olga Rodríguez, Judit Grueso, Joaquin Arribas, Javier Cortés, Cristina Saura, Alan Lau, Susan Critchlow, Brian Dougherty, Carlos Caldas, Gordon B. Mills, J. Carl Barrett, Josep V. Forment, Elaine Cadogan, Christopher J. Lord, Cristina Cruz, Judith Balmaña, Mark J. O'Connor
Publikováno v:
Scientia
Cáncer de mama y de ovario; Inhibición WEE1 Càncer de mama i d'ovari; Inhibició WEE1 Breast and ovarian cancer; WEE1 inhibition Purpose: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors
Autor:
Yann Wallez, Theresa Proia, Azadeh Cheraghchi-Bashi-Astaneh, Ankur Karmokar, Zena Wilson, Suzanne Randle, Mark Anderton, Stephen Durant, Elisabetta Leo, Alan Lau, Mark O'Connor, Jerome Mettetal
Publikováno v:
Cancer Research. 82:5298-5298
Background: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate composed of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. T-DXd is approved for patients with HER2+ metastatic breast
Autor:
Geoffrey I. Shapiro, Bristi Basu, Anthony El-Khoueiry, Sophie Postel-Vinay, Seock-Ah Im, Sun Young Rha, Claire F. Friedman, Antoine Italiano, Yong Man Kim, Myong Cheol Lim, Rene Roux, Joyce F. Liu, Elhan Sanai, Simon A. Smith, Claire Smith, Sarah El Farhi, Alan Lau, Natalia Lukashchuk, Emma Dean, Matthew G. Krebs
Publikováno v:
Cancer Research. 82:CT201-CT201
Background: The majority of BRCA-mutant or HRR-deficient ovarian cancers are initially sensitive to PARP inhibitors (PARPis) but eventually develop resistance. The most commonly reported PARPi resistance mechanisms are (1) reversal of HRR deficiency
Autor:
Brunella Felicetti, Paul Frewer, Juanita Lopez, Anthony El-Khouiery, Glen Clack, Christine Stephens, Simon J. Hollingsworth, Matthew G Krebs, Alan Lau, Andrew Goldwin, Alienor Berges, Jean-Charles Soria, Gemma N Jones, Sophie Postel-Vinay, Itziar Irurzun-Arana, Emma Dean, Sy Amy Cheung, Timothy A. Yap, Andrew J. Pierce, Simon Smith
Publikováno v:
Yap, T, Krebs, M, Postel-Vinay, S, El-Khouiery, A, Soria, J-C, Lopez, J, Berges, A, Cheung, S Y A, Irurzan-Arana, I, Goldwin, A, Felicetti, B, Jones, G, Lau, A, Frewer, P, Pierce, A, Clack, G, Stephens, C, Smith, S, Dean, E J & Hollingsworth, S J 2021, ' Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a Phase I study ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-21-1032
Purpose: This study reports the safety, tolerability, MTD, recommended phase II dose (RP2D), pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of ceralasertib combined with carboplatin in patients with advanced solid tumors.